Novartis (NVS) to Release Quarterly Earnings on Thursday

Novartis (NYSE:NVS) will announce its earnings results before the market opens on Thursday, July 18th. Analysts expect the company to announce earnings of $1.85 per share for the quarter.

Novartis (NYSE:NVS) last released its earnings results on Tuesday, April 23rd. The company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.73 by $0.07. The firm had revenue of $11.83 billion for the quarter, compared to the consensus estimate of $11.50 billion. Novartis had a return on equity of 32.15% and a net margin of 31.33%. On average, analysts expect Novartis to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Novartis Stock Performance

Shares of NYSE:NVS opened at $109.94 on Thursday. The firm has a market capitalization of $224.72 billion, a PE ratio of 14.84, a P/E/G ratio of 1.66 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.90 and a quick ratio of 0.71. The business has a 50-day moving average of $103.86 and a two-hundred day moving average of $101.73. Novartis has a 12 month low of $92.19 and a 12 month high of $109.95.

Analysts Set New Price Targets

NVS has been the subject of several research analyst reports. Jefferies Financial Group upped their price target on Novartis from $121.00 to $122.50 and gave the stock a “buy” rating in a research note on Tuesday, July 2nd. BMO Capital Markets upped their price target on Novartis from $114.00 to $116.00 and gave the stock a “market perform” rating in a research note on Wednesday, April 24th. Barclays upgraded Novartis to a “strong sell” rating in a research note on Monday, June 24th. Finally, The Goldman Sachs Group assumed coverage on Novartis in a research note on Thursday, May 30th. They issued a “buy” rating and a $120.00 target price for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $118.13.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.